Alan Dal Pra1, Cedric Panje2, Thomas Zilli3, Winfried Arnold4, Kathrin Brouwer5, Helena Garcia6, Markus Glatzer2, Silvia Gomez7, Fernanda Herrera8, Khanfir Kaouthar9, Alexandros Papachristofilou10, Gianfranco Pesce11, Christiane Reuter12, Hansjörg Vees13, Daniel Rudolf Zwahlen14, Daniel Engeler15, Paul Martin Putora2. 1. Department of Radiation Oncology, Bern University Hospital, Inselspital Bern, Freiburgstrasse, 3010, Bern, Switzerland. alan.dalpra@insel.ch. 2. Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 3. Department of Radiation Oncology, Hospitaux Universitaires de Génève, Génève, Switzerland. 4. Department of Radiation Oncology, Luzerner Kantonsspital, Luzerner, Switzerland. 5. Department of Radiation Oncology, Stadtspital Triemli, Zürich, Switzerland. 6. Department of Radiation Oncology, Universitätsspital Zürich, Zürich, Switzerland. 7. Department of Radiation Oncology, Kantonsspital Aarau, Aarau, Switzerland. 8. Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 9. Department of Radiation Oncology, Hôpital du Valais, Sion, Switzerland. 10. Department of Radiation Oncology, Universitätsspital Basel, Basel, Switzerland. 11. Department of Radiation Oncology, EOC Bellinzona, Bellinzona, Switzerland. 12. Department of Radiation Oncology, Kantonsspital Münsterlingen, Münsterlingen, Switzerland. 13. Department of Radiation Oncology, Klinik Hirslanden, Zürich, Switzerland. 14. Department of Radiation Oncology, Kantonsspital Graubünden, Chur, Switzerland. 15. Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Abstract
INTRODUCTION: Although salvage radiotherapy (SRT) for PSA recurrence after radical prostatectomy provides better oncological outcomes when delivered early, in the absence of detectable disease many patients are treated for macroscopic locally recurrent tumors. Due to limited data from prospective studies, we hypothesized an important variability in the SRT management of these patients. Our aim was to investigate current practice patterns of SRT for local macroscopic recurrence after radical prostatectomy. MATERIAL AND METHODS: A total of 14 Swiss radiation oncology centers were asked to complete a survey on treatment specifications for macroscopic locally recurrent disease including information on pretherapeutic diagnostic procedures, dose prescription, radiation delivery techniques and androgen deprivation therapy (ADT). Treatment recommendations on ADT were analyzed using the objective consensus methodology. RESULTS: The majority of centers recommended pretreatment magnetic resonance imaging (MRI) of the pelvis and choline positron emission tomography (PET). The median prescribed dose to the prostate bed was 66 Gy (range 65-72 Gy) with a boost to the macroscopic lesion used by 79% of the centers with a median total dose of 72 Gy (range 70-80 Gy). Intensity-modulated rotational techniques were used by all centers and daily cone beam computed tomography (CT) was recommended by 43%. The use of concomitant ADT for any macroscopic recurrence was recommended by 43% of the centers while the remaining centers recommended it only for high-risk disease, which was not consistently defined. CONCLUSION: We observed a high variability of treatment paradigms when SRT is indicated for macroscopic local recurrences after prostatectomy. These data reflect the need for more standardized approaches and ultimately further research in this field.
INTRODUCTION: Although salvage radiotherapy (SRT) for PSA recurrence after radical prostatectomy provides better oncological outcomes when delivered early, in the absence of detectable disease many patients are treated for macroscopic locally recurrent tumors. Due to limited data from prospective studies, we hypothesized an important variability in the SRT management of these patients. Our aim was to investigate current practice patterns of SRT for local macroscopic recurrence after radical prostatectomy. MATERIAL AND METHODS: A total of 14 Swiss radiation oncology centers were asked to complete a survey on treatment specifications for macroscopic locally recurrent disease including information on pretherapeutic diagnostic procedures, dose prescription, radiation delivery techniques and androgen deprivation therapy (ADT). Treatment recommendations on ADT were analyzed using the objective consensus methodology. RESULTS: The majority of centers recommended pretreatment magnetic resonance imaging (MRI) of the pelvis and choline positron emission tomography (PET). The median prescribed dose to the prostate bed was 66 Gy (range 65-72 Gy) with a boost to the macroscopic lesion used by 79% of the centers with a median total dose of 72 Gy (range 70-80 Gy). Intensity-modulated rotational techniques were used by all centers and daily cone beam computed tomography (CT) was recommended by 43%. The use of concomitant ADT for any macroscopic recurrence was recommended by 43% of the centers while the remaining centers recommended it only for high-risk disease, which was not consistently defined. CONCLUSION: We observed a high variability of treatment paradigms when SRT is indicated for macroscopic local recurrences after prostatectomy. These data reflect the need for more standardized approaches and ultimately further research in this field.
Authors: X Allen Li; Jian Z Wang; Paul A Jursinic; Colleen A Lawton; Dian Wang Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler Journal: N Engl J Med Date: 2017-02-02 Impact factor: 91.245
Authors: Nicholas G Zaorsky; Joshua D Palmer; Mark D Hurwitz; Scott W Keith; Adam P Dicker; Robert B Den Journal: Radiother Oncol Date: 2015-05-28 Impact factor: 6.280
Authors: Jacob G Scott; Anders Berglund; Michael J Schell; Ivaylo Mihaylov; William J Fulp; Binglin Yue; Eric Welsh; Jimmy J Caudell; Kamran Ahmed; Tobin S Strom; Eric Mellon; Puja Venkat; Peter Johnstone; John Foekens; Jae Lee; Eduardo Moros; William S Dalton; Steven A Eschrich; Howard McLeod; Louis B Harrison; Javier F Torres-Roca Journal: Lancet Oncol Date: 2016-12-18 Impact factor: 41.316
Authors: Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-23 Impact factor: 7.038
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Gaël Amzalag; Olivier Rager; Claire Tabouret-Viaud; Michael Wissmeyer; Electra Sfakianaki; Thomas de Perrot; Osman Ratib; Raymond Miralbell; Giampiero Giovacchini; Valentina Garibotto; Thomas Zilli Journal: Front Oncol Date: 2016-03-31 Impact factor: 6.244
Authors: Felipe Couñago; Ana Aurora Díaz Gavela; Gemma Sancho; Irene Ortiz; Francisco José Marcos; Manuel Recio; Julio Fernández; Raquel Cano; Mar Jiménez; Israel J Thuissard; David Sanz-Rosa; Juan Castro Nováis; Eduardo Pardo; Yolanda Molina; Hugo Pérez García; Elia Del Cerro Journal: Rep Pract Oncol Radiother Date: 2019-08-08
Authors: Sung Uk Lee; Kwan Ho Cho; Jin Ho Kim; Young Seok Kim; Taek-Keun Nam; Jae-Sung Kim; Jaeho Cho; Seo Hee Choi; Su Jung Shim; Jin Hee Kim; Ah Ram Chang Journal: Technol Cancer Res Treat Date: 2021 Jan-Dec
Authors: Jörg Tamihardja; Leonie Zehner; Philipp E Hartrampf; Sinan Cirsi; Sonja Wegener; Andreas K Buck; Michael Flentje; Bülent Polat Journal: Cancers (Basel) Date: 2022-10-10 Impact factor: 6.575